Supply of SOFLAX tablet-film coated by Ascent Pharmaceuticals Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, serves to regulate therapeutic goods to ensure public health and safety. This legislation was introduced to address the need for a robust framework governing the supply, quality, and safety of therapeutic goods within Australia. One of the key gaps it aimed to fill was the regulation of the therapeutic goods market to prevent the distribution of unsafe or substandard products. In this context, the Act empowers the Secretary to the Department of Health and Ageing to delegate certain functions, including the ability to provide consent for deviations from specified therapeutic goods standards. The policy objective of the Act is to maintain and enhance the quality, safety, and efficacy of therapeutic goods available to the public. This specific legislative instrument under Section 14 and 14A of the Act allows for the exemption of certain products from specified regulatory requirements, subject to conditions designed to protect public health.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, including the approval and oversight of the supply of therapeutic goods. Section 14A of the Act allows for the Minister or a delegate, such as Mayada Kaylali in this instance, to provide consent for a company to supply a therapeutic good that does not comply with specific regulatory standards. This provision is designed to address situations where strict adherence to the regulations may not be feasible or necessary, and where the therapeutic benefit of the product outweighs the potential risks. In this case, the delegate's consent allows Ascent Pharmaceuticals Pty Ltd to supply SOFLAX tablet-film coated (AUST R 91684) that does not comply with the specified limits for sennosides content in Therapeutic Goods Order No. 78, subject to certain conditions designed to mitigate potential risks to public health. The consent is specifically tailored to ensure that the product's sennosides content remains within defined limits at both release and expiry, ensuring that the therapeutic benefit of the product is maintained while minimising any associated risks. This legislative mechanism ensures that the Therapeutic Goods Act can be flexibly applied to promote public health while accommodating practical and scientific considerations in the supply of therapeutic goods.

Key Provisions

The key sections of this notice are sections 14, 14A, and 15 of the Therapeutic Goods Act 1989 (the Act). Section 14 allows for the delegate of the Secretary to the Department of Health and Ageing to give consent for the supply of therapeutic goods that do not meet certain requirements of the Therapeutic Goods Orders. In this case, section 14A is also invoked to specify the particular therapeutic goods (SOFLAX tablet-film coated with AUST R 91684) and the specific non-compliance with Therapeutic Goods Order No. 78 concerning the sennosides content limits in the finished product specifications. This consent, granted by Mayada Kayali as the delegate, is subject to certain conditions outlined in section 15 of the Act. The conditions include specific limits for the content of sennosides in the finished product specifications, which are set at 97.5-110.0% at release and 92.5-110.0% at expiry. These conditions must be adhered to, ensuring that the product complies with all other requirements of Therapeutic Goods Order No. 78 apart from the specified sennosides content limits. The obligations imposed on Ascent Pharmaceuticals Pty Ltd under this notice include ensuring that the SOFLAX tablet-film coated products meet the specified sennosides content limits at both release and expiry. The company must also ensure that all other requirements of Therapeutic Goods Order No. 78 are fulfilled, except for the exempted sennosides content limits. This involves regular monitoring and quality control measures to maintain compliance with these standards. Any changes in the manufacturing process that could affect the sennosides content must be reported to the delegate of the Secretary, and appropriate documentation should be maintained to demonstrate compliance with these conditions. Failure to comply with the conditions set out in this notice can lead to various consequences. Under the Therapeutic Goods Act 1989, breaches of the conditions can be considered offences. The penalties for such breaches can include substantial fines, with maximum penalties set out in the Act. Additionally, non-compliance may result in legal actions being taken against Ascent Pharmaceuticals Pty Ltd, potentially leading to court-ordered penalties and the cessation of the supply of the non-compliant therapeutic goods. In severe cases, there could be implications for the company's registration and ability to supply therapeutic goods in the future. It is imperative for Ascent Pharmaceuticals Pty Ltd to adhere strictly to the specified conditions to avoid these potential legal and financial repercussions.